Crossmark

Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer

Crossref DOI link: https://doi.org/10.1038/s41416-021-01592-7

Published Online: 2021-10-23

Published Print: 2022-01-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Arai, Hiroyuki

Xiao, Yi

Millstein, Joshua

Wang, Jingyuan

Battaglin, Francesca

Kawanishi, Natsuko

Jayachandran, Priya

Soni, Shivani

Zhang, Wu

Mancao, Christoph

Salhia, Bodour

Mumenthaler, Shannon M.

Parikh, Aparna R. https://orcid.org/0000-0002-5245-7841
Lenz, Heinz-Josef https://orcid.org/0000-0003-2178-9568
Funding

Funding for this research was provided by:

Dhont Family Foundation
License Information

Text and Data Mining valid from 2021-10-23

Version of Record valid from 2021-10-23
More Information

Article History

Received: 28 July 2021

Revised: 27 September 2021

Accepted: 6 October 2021

First Online: 23 October 2021

Competing interests

: The authors declare no competing interests.

: All patients provided informed consent for molecular research prior to study enrollment. The study protocol was approved by the Institutional Review Boards of each participating institution and was conducted in accordance with the tenets of the Declaration of Helsinki, as well as the Good Clinical Practice and REMARK guidelines.

: Not applicable.

Document is current

Any future updates will be listed below